Abstract
Proliferating cell nuclear antigen (PCNA), a potential anticancer target, forms a homotrimer and is required for DNA replication and numerous other cellular processes. The purpose of this study was to identify novel small molecules that modulate PCNA activity to affect tumor cell proliferation. An in silico screen of a compound library against a crystal structure of PCNA and a subsequent structural similarity search of the ZINC chemical database were carried out to derive relevant docking partners. Nine compounds, termed PCNA inhibitors (PCNA-Is), were selected for further characterization. PCNA-I1 selectively bound to PCNA trimers with a dissociation constant (Kd) of ∼0.2 to 0.4 μM. PCNA-Is promoted the formation of SDS-refractory PCNA trimers. PCNA-I1 dose- and time-dependently reduced the chromatin-associated PCNA in cells. Consistent with its effects on PCNA trimer stabilization, PCNA-I1 inhibited the growth of tumor cells of various tissue types with an IC50 of ∼0.2 μM, whereas it affected the growth of nontransformed cells at significantly higher concentrations (IC50, ∼1.6 μM). Moreover, uptake of BrdU was dose-dependently reduced in cells treated with PCNA-I1. Mechanistically the PCNA-Is mimicked the effect of PCNA knockdown by siRNA, inducing cancer cell arrest at both the S and G2/M phases. Thus, we have identified a class of compounds that can directly bind to PCNA, stabilize PCNA trimers, reduce PCNA association with chromatin, and inhibit tumor cell growth by inducing a cell cycle arrest. They are valuable tools in studying PCNA function and may be useful for future PCNA-targeted cancer therapy.
Footnotes
↵ The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
This work was supported in part by the National Institutes of Health National Cancer Institute [Grants R01-CA131137-01A1, R01-CA121289]; and by Millennium Scholar Funds from the University of Cincinnati Cancer Institute.
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
ABBREVIATIONS:
- PCNA
- proliferating cell nuclear antigen
- RFC
- replication factor C
- siRNA
- small interfering RNA
- PI
- propidium iodide
- MTT
- 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- FBS
- fetal bovine serum
- PCNA-I
- PCNA inhibitor
- PMSF
- phenylmethylsulfonyl fluoride
- PAGE
- polyacrylamide gel electrophoresis
- NP-E
- NP-40-extractable
- NP-R
- NP-40-resistant
- BrdU
- bromodeoxyuridine
- PCNA-I1
- N′-[(1-hydroxy-2-naphthyl) methylene]-3-methyl-2-thiophenecarbo-hydrazide
- PCNA-I2
- N′-[(2-hydroxy-1-naphthyl) methylene]-1H-pyrazole-5-carbohydrazide)
- SPR
- surface plasmon resonance
- SFM
- serum-free medium.
- Received January 10, 2012.
- Accepted March 7, 2012.
- Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|